| ||Human papillomavirus (HPV) is the first pathogen to be recognised as the causative agent in virtually 100% of cases of a specific cancer type. This suggests there could be effective vaccines against cancers, and for HPV there are indeed two commercially produced vaccines. A comprehensive, school-based program has been rolled out in Australia, and the good coverage achieved now bears witness to a reduction in the burden of HPV-related diseases.
In this issue of Sexual Health, guest edited by Julia Brotherton, Kit Fairley, Dorota Gertig, Marion Saville and Suzanne Garland, authors highlight research and experiences relevant to HPV, from vaccine manufacture, evaluation of disease burden, screening and treatment, vaccine rollout, and impact evaluation. What are the successes and what were the challenges for this national public health program? What will reduce the burden of HPV-related disease on all people? What approaches can be adopted or need modification for countries with less well-funded public health programs, and to avoid increasing inequity within a country? These are some of the subjects explored in this special collection.